Bone marrow aspirates are composed of two cellular compartments, an abundant buffy coat suspension and a minor particulate fraction. The particulate fraction is routinely removed by filtration prior to transplantation in order to reduce the risk of embolism. This study shows that the filter-retained fraction includes many multicellular complexes, previously defined as haematons. A haematon is a finely arborized stromal-web which is tightly packed with haemopoietic progenitor cells and differentiated postmitotic cells. Comparison of the pooled buffy coat and the filter-retained materials from healthy donors showed that the haematon fraction contained 8-40 × 10 6 CD34 + cells, 20-115 × 10 3 high proliferative potential colony-forming cells (HPP-CFC) and 0.49-2.67 × 10 6 granulocyte-macrophage colony-forming unit (GM-CFU) which constituted 24 ± 8% (10-36; n = 8) of the total GM-CFU population harvested. Similar, but more variable recoveries of GM-CFU were obtained from the haematon fractions from patients with breast cancer (21 ± 13%; n = 10), Hodgkin's disease (33 ± 19%; n = 4), non-Hodgkin's lymphoma (21 ± 18; n = 7), but the recovery was lower from patients with acute myelogenous leukaemia (AML) (13 ± 13%; n = 6). The haematon fraction was enriched in CD34 + cells (2.
using filter-retained haematons, provides a rational source of BM cells for large scale experimental and/or clinical studies on haemopoietic stem cells and on critical accessory stromal cells. Keywords: BM harvesting; haematon; stem cell; LTC-IC/CAFC; CD34 + cell expansion
Haemopoietic stem cell transplantation (HSCT) is routinely used to treat haematological malignancies, congenital or acquired BM failures and solid tumours. 1 But graft failure may occur after intensive chemotherapy and radiation therapy despite recent improvements in methodology. Failure may be due to insufficient grafted HSCs, [2] [3] [4] [5] an acute graftversus-host reaction and graft rejection, 6 ,7 too many residual malignant cells 8 or severe opportunistic infection. Defective stromal cell function may also contribute to graft failure, because the stromal cell compartment in the host BM was not replaced by donor derived cells following transplantation, 9 and persistent, not yet fully defined abnormalities of the stromal cells have been described before treatment in patients with malignant haemopathies, [10] [11] [12] [13] [14] and following intensive chemotherapy or radiation. 15 The development of optimal conditioning regimens, 16 the use of selective cytotoxic agents to purge the BM of malignant cells, 17 the use of recombinant haemopoietic growth factors (rHGFs) to accelerate BM regeneration, 18 and most recently, the use of peripheral stem cells, 19 purified CD34 + or CD34 + CD38 − cells 20 and umbilical cord blood cells 21, 22 have all considerably improved the efficacy of HSCT technology and have opened up new perspectives. The ex vivo expansion of CD34 + cells in the presence of rHGFs in stroma-free suspension cultures is another promising technique for obtaining more transplantable HSC. This system provides over 2 log increases in GM-CFU populations and a greater than 10-fold increase in HPP-CFC when used with various combinations of rIL-1␤, rIL-3, rIL-6, rGM-CSF, rG-CSF and rSCF. [23] [24] [25] [26] [27] [28] The HSC population, however, remains at around the initial input level, 15, 16 or declines 17, 18 in these cultures. New factor combinations with Flt-3 ligand, SCF, IL-3, IL-6, G-CSF and NGF in defined medium, have improved the amplification of LTC-IC population 30-to 50-fold. 29, 30 HSCs with competitive marrow repopulating ability are quiescent, as was shown using hydroxyurea and the tritiated thymidine suicide technique. 31 Their homing in the BM fol-lowing infusion and their reactivation require focal contact with rare stromal cell niches that help to ensure the tissue specificity of the BM microenvironment. 32 This has been shown using ectopic implants of BM tissue, 33 in vivo reconstitution experiments between genetically anaemic mice, W/W and Sl/Sl, 34 and long-term cultures of BM (LTBMC), where the adherent stromal cell layer supported the longterm expansion and renewal of CFU-S, 35, 36 and marrowrepopulating HSCs. [37] [38] [39] Stromal cells form an interactive network with each other and with haemopoietic cells in the BM, so that the fate of those HSCs which are firmly associated with stromal cells is largely unknown during the conditioning of BM for transplantation. It has been postulated that critical stromal cells and haemopoietic progenitor cells form solid complexes which can be isolated from freshly aspirated human BM. A cohort of preformed cell complexes, termed haematons, has been identified in the very low density, floating layer of normal human BM aspirates. 13 Haematon complexes can also be isolated from the gently dispersed BM of mice using repeated 1 g sedimentations of the haematons and decanting the buffy coat suspension. 40 Recent studies have shown that the haematon is a finely arborized stromal framework including endothelial cells, fibroblasts, lipidladen cells and resident macrophages. These spherical particles are tightly packed with haemopoietic cells, including primitive cells with MRA, granulocyte CAFC, CFU-S d12 in the mouse haematon, and HPP-CFC, BFU-E, GM-CFU, plus differentiated postmitotic cell populations in both human and mouse haematons. 40 Haematon complexes are always present in the BM aspirates of healthy donors and cancer patients at remission, but they are virtually absent from the BM aspirates of patients with advanced myelodysplasia, acute myelogenous leukaemia (AML), and chronic myeloid leukaemia (CML) patients at first presentation. 13 The number of cancer patients who could benefit from autologous HSCT is steadily increasing. The use of leukapheresis material (PB-HSC) greatly facilitates HSCT and it has already replaced BMT in several pathologies. 16, 18, 19 In consequence, human BM samples containing HSC and stromal cells are less available for experimental and preclinical studies. The presence of haematons in normal BM and in patients at haematological remission, plus the fact that the majority of haematon particles are over 50 m in diameter, 13 prompted us to isolate and characterize the cell fraction which is routinely removed by filtration from the pooled BM before infusion into patients. This report shows that a large number of haematon particles can be recovered from pooled BM aspirates harvested for HSCT from healthy donors, or from cancer patients in clinical remission. This usually wasted BM fraction can be recovered and used to provide large numbers of stromal cells and stromal cellassociated primitive haemopoietic progenitor cells. Our data suggest that 'unpleasant lumps' should be saved, and stored, unless used fresh, particularly now, when fewer and fewer BM samples containing haematons are available for experimental and preclinical studies.
Materials and methods

Patients
Bone marrow cells were obtained from healthy donors (allo-HSCT; n = 8) and from patients who had undergone auto-HSCT (n = 27), at the time of large scale BM harvest. The patients included 10 breast cancer, four Hodgkin's disease (HD), seven non-Hodgkin's lymphoma (NHL) and six AML. They were advised of the risk of marrow aspiration and gave their informed consent.
Human BM preparations
BM was aspirated under general anesthetic in multiple 5-10 ml aliquots into 20 IU/ml preservative-free heparin. The pooled BM was filtered ((1000 m, 500 m and 200 m meshes; Bone Marrow Collection Container with Flexible Pre-filter, Baxter Healthcare Corporation, Fenwal Division, Deerfield, IL, USA), concentrated and processed immediately for transplantation or for freezing according to standard techniques.
Purification of the buffy coat, mononuclear cell and haematon fractions: Aliquots (5 ml) of pooled, filtered BM were taken to prepare the buffy coat and mononuclear cell (MNC) fractions, and the filter-retained material was used to obtain the haematon fraction. The BM suspension was diluted (1:1) with ice-cold phosphate-buffered saline (PBS) containing 10 IU heparin/ml, then two equal volumes were layered on Ficoll-Hypaque density gradients (d = 1.077 g cm 3 ). The low density layers were carefully recovered following either a 40 min 1 g sedimentation to obtain the red blood cell-depleted buffy coat (BC), and from the other tube following a 20 min 400 g centrifugation to isolate the MNC fraction.
The haematon particles were recovered from the filters by washing them vigorously with ice-cold Ca-Mg-free PBS/5% fetal calf serum (FCS), containing 20 IU heparin. Intact haematon complexes were further purified by flotation over PBS-FCS. Alternatively, 15-20 ml Dulbecco's PBS-5% FCS solution containing purified 0.1% collagenase type-II and type-IV (Clostridiopeptidase A, E.C 3.4.24.3; Sigma Chemical Co, St Louis, MO, USA) and 10 IU heparin/ml was injected directly into the filters: this gave rapid recovery (10 min at 37°C) of all filter-retained haematon particles as a suspension. The haematon fractions were dispersed in the collagenase solution at 37°C for 60 min, using gentle shaking at 10 min intervals. The suspension was centrifuged (800 g, 10 min), the floating yellowish lipid layer and the supernatant were carefully removed and discarded, and the cell pellet was washed three times in icecold complete medium.
Purification of CD34
+ cells from the haematon fraction by high-gradient magnetic cell sorting (MACS): 10 8 enzymatically dissociated cells were washed in ice-cold PBS containing 0.5% BSA, 0.5 IU/ml DNAse II and 0.01% Naazide (washing buffer), centrifuged and resuspended in 500 l washing buffer. This suspension was incubated with monoclonal anti-CD34 antibody (QBEND/10, mouse IgG1) bearing paramagnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). 41 The cells were sorted on Mini-MACS column, washed in culture medium and the CD34 − and the CD34 + cell populations were studied.
In vitro assays for clonogenic cells
Semisolid cultures for myeloid and erythroid colonyforming cells: High proliferative potential (HPP-CFC), granulocyte-macrophage (GM-CFU) and erythroid (burstforming unit, BFU-E) progenitor cells were determined in a modified 13, 14 double layer methylcellulose/agar culture system. 42 Briefly, a 0.7 ml 0.5% agar in a 35-mm Petri dish (ATGC, Biotechnologie, Noisy-le-Grand, France), was overlaid with test cells in 1.5 ml 0.9% complete methylcellulose medium containing 1% BSA and 0.1 mmol/l ␤-mercaptoethanol (␤-ME) (HCC 4230; Stem Cell Technologies (STI), Vancouver, British Columbia, Canada). The human cultures were stimulated with a mixture of human recombinant haemopoietic growth factors (hrHGFs): 50 IU hrIL-1␤, 4 ng hrIL-3, 20 ng hrGM-CSF, 20 ng hrG-CSF and 50 IU hrM-CSF (Genzyme, Cambridge, MA, USA) per ml for myeloid cultures. GM-CFU were scored after 14 days of incubation at 37°C in a humidified atmosphere of 5% CO 2 in air and large sized HPP-CFU (Ͼ1 mm in diameter) were determined on days 28-42 from the same culture dishes according to standard criteria. 42 Erythroid progenitors were assayed by stimulating separate cell cultures with hrHGFs plus 10 ng hrSCF and 3 U Epo (STI) per ml; monofocal CFU-E and large multifocal BFU-E populations were counted on day 14.
Assay for fibroblast colony-forming units (F-CFU):
The frequencies of F-CFU populations in the buffy coat and haematon fractions were determined in standard liquid BM cultures, as described previously. 13, 14 The fibroblast progenitor cells in the haemopoietic colonies grown in semisolid culture were studied in secondary liquid cultures. Single HPP-CFU were picked out using a Pasteur pipette under a stereomicroscope and GM-CFUs in individual Petri dishes cultured in methylcellulose for 28 days were pooled. The colonies were dispersed in 2 ml complete LTC medium and seeded in 35-mm Petri dishes. The adherent F-CFU populations were counted after 7-14 days of culture under a Zeiss STEMI SV8 stereomicroscope (Zeiss, Oberkochen, Germany). In some experiments stromal cultures were irradiated (2000 rad) and were overlayered with 10 3 CD34
+ cells to analyse the CA forming competence of colonyderived stromal cells.
Assay for long-term culture initiating cells (LTC-IC/CAFC) by limiting dilution analysis (LDA):
The frequency of LTC-IC/CAFC was determined by LDA. 39, [43] [44] [45] The longterm culture (LTC) medium consisted of IMDM, enriched in BSA, soya bean lecitin and human transferrin (Flow Laboratories, Irvine, UK), and was supplemented with 0.5 mg/l ascorbic acid, 37 mg/l myo-inositol, 10 mg/l folic acid, 50 m ␤-ME, 12.5% horse serum, 12.5% FCS, penicillin/streptomycin and freshly diluted 5 m hydrocortisone hemisuccinate (Sigma). Nutritive stromal feeder cells were prepared, using the haematon fraction of BM, 12-14 days prior to LDA experiments. 2 × 10 7 dispersed cells were seeded in 10 ml LTC medium in 25 cm 2 T-flasks (ATGC). The cultures were maintained at 33°C with weekly half medium changes. The adherent layer was trypsinized, washed and aliquots of 3 × 10 5 cells in 100 l LTC medium were seeded in 96-well flat-bottom microplates (ATGC). A total dose of 20 Gy was given at 1.4 Gy/min from a IBL 637 gamma irradiator equipped with a 137 Cs source (Cis-Bio International/ORIS Industry, France) and 24 h later serial 1/2 dilutions of test cells in 100 l medium (24-parallel wells) were seeded over the feeder cells. Half of the spent medium was replaced with fresh medium at weekly intervals. Negative and positive wells were counted on day 14 and day 35 of cultures under a Zeiss ICM-405 inverted phase contrast microscope. Productive colonies included at least five phase-dark cells underneath stromal cells and several hundred to a thousand cells on top of the stromal cells (cobblestone area, CA). Positive wells were trypsinized on day 35 and tested for GM-CFU. Usually more than 90% of positive wells contained Ͼ5 GM-CFU (range 5-750). The frequency of LTC-IC/CAFC (1 test cell/× input cells) was extrapolated from the linear regression curves. 39, 43, 45 
Long-term cultures
The abilities of the buffy coat and haematon fractions to produce cells were studied in different liquid culture systems. These cultures were maintained without an irradiated stromal feeder.
Long-term liquid bone marrow cultures (LTBMC):
Buffy coat cells and haematons were seeded at 5 × 10 5 cells per 2 ml LTC medium in 24-well Nunclon tissue culture dishes (Nunclon, Roskilde, Denmark). The myeloid LTC medium was identical to that described for LTC-IC/CAFC assays. Cell production was determined using semisolid colony assays in the non-adherent fraction and in adherent cells dispersed with 0.1% collagenase type II/IV and washed twice in IMDM/20% FCS medium.
Stromal-free suspension culture of haematon-derived CD34
+ cells: CD34 + cells were purified from the haematon fraction using immunomagnetic cell sorting (Mini-MACS). 10 5 cells were suspended in 3 ml culture medium containing IMDM medium, BSA, soya bean lecithin, human transferrin, 20% FCS, 50 m ␤-ME and antibiotics. Cells were stimulated with hrHGFs, including: 0.5 ng IL-1␤, 10 ng IL-3, 10 ng IL-6, 20 ng GM-CSF and 10 ng SCF (KL) per ml culture medium and TNC and colony-forming cells were measured at the indicated intervals. The suspension cultures were diluted 10-fold with fresh medium containing HGFs at weekly intervals to maintain the optimal growth rate and cell concentration, usually 0.1-3 × 10 6 cells per ml.
Cytological techniques
Cell counting, staining and vitality tests: Red blood cells were lysed in 0.1% acetic acid and total nucleated cells were counted in a haemocytometer. BM film and cytospin preparations were stained with May-Grünwald Giemsa. Cell viability was routinely determined by trypan blue (0.2%) exclusion. Cells undergoing apoptotic cell death in LTCs were analysed by FITC-labelled Annexin-V-PI double staining according to instructions provided by Coulter (Miami, FL, USA). Briefly, 5 × 10 5 cells were spun (400 g, 7 min), suspended in 490 l incubation buffer with 5 l FITC-Annexin-V and 5 l PI and incubated for 10 min at 4°C in the dark. Cells and apoptotic bodies were analysed under a Zeiss ICM-405 epifluorescence microscope using a 515-565 nm filter for FITC and a 590 nm filter for IP.
Immunofluorescence analysis: Collagenase-dissociated BM fractions (5 × 10 5 cells) were kept overnight in PBS/10% FCS at 4°C, washed in PBS with 1% BSA/0.1% Na-azide and incubated for 30 min with phycoerythrin (PE)-conjugated mouse anti-human IgG directed against the CD34 antigen (HPCA-2), or with FITC-labelled mouse anti-human CD4, CD8 or CD20 monoclonal antibodies (Becton Dickinson, San Jose, CA, USA). Control aliquots were incubated with PE-or FITC-labelled isotype antibodies. The cells were washed twice in 1% BSA/PBS, and the percentage of labelled cells was determined in an Epics-II (Coulter counter) fluorescence-activated cell sorter.
Micromanipulation and microphotography:
Single haematon units, or the core structure of haematons were isolated under a Zeiss ICM-405 inverted microscope using a micromanipulator to control a glass microcapillary attached to a 10 l Hamilton syringe. The filter-retained and freshly isolated haematon preparations were photographed with a Contax-167 MT camera. Colonies grown in semisolid culture were photographed under a Zeiss SV-8 stereomicroscope with dark field illumination, and liquid cell cultures were photographed in a Zeiss ICM-405 inverted phase contrast microscope.
Statistical analysis
Cells and colonies were counted in triplicate cultures. The significance of differences between experimental data was calculated using Student's t-test. Limiting dilution analyses of LTC-IC/CAFC populations were performed on 24 parallel microcultures using 3 serial 1/2 dilutions. The input number of cells seeded per well was plotted against log% of negative wells on day 35 of culture, then the frequency of LTC-IC/CAFC (1 test cell/× input cells) was extrapolated from the liner regression curves at the −log% = −0.37. 39, [43] [44] [45] Statistical analyses were performed with StatMate and graphics with Prism software (GraphPad, San Diego, CA, USA).
Results
Purification and characteristics of the filter-retained material from pooled BM aspirates
The pooled BM, usually 1.4-1.6 l, was passed through a prefilter (1000 m mesh) and two finer filters (500 and 200 m), and the particulate fraction retained by the three filters was recovered by vigorous washing with ice-cold PBS-FCS through a 18 G needle. Figure 1a shows that the filters were tightly packed with spheroid complexes, haematons. This technique produced several milliliters of intact, floating haematons ( Figure 1b, Table 1 ). Single haematon complexes were isolated from diluted samples by micromanipulation and placed in organotypic semisolid microculture. They produced spontaneously 20-175 × 10 3 cells (n = 120) and up to 1200 × 10 3 cells in the presence of hrHGFs (n = 240) after 14 days in culture (Figure 1c) .
The filters were also incubated with 0.1% collagenase type-II/IV in DPBS/FCS or complete LTC medium to convert the haematons to a cell suspension. This step was (P) Significance of difference in CFU-GM values that were recovered in the haematon fractions was calculated between healthy donors and disease groups. NS = non significant; S = P Ͻ 0.05. There was a significant difference between patients at distinct clinical status: the % CFU-GM recovery in the haematon fraction was 19.8 ± 11% in patients at CR1, 31 ± 15% at CR2 (P Ͼ 0.05) and 4.7 ± 3% at PR (P Ͻ 0.001).
required to dissociate the stromal cell framework prior to quantitative cell assays, and to elimininate the cell-free yellowish lipid material that was always present in the haematons. Enzymatically dissociated haematons cultured in semisolid medium for 28 days with rhHGFs, formed typical, large HPP-CFU (Ͼ1 mm). These and previous 13, 42 studies indicated that the haematon material retained on the filters may contain large numbers of haemopoietic progenitor cells.
Quantitative cell recovery from the buffy coat and filterretained haematon fractions
The numbers of TNC and haemopoietic progenitor cells in the pooled and filtered buffy coat and filter-retained haema-ton fractions were then measured. While recovery of TNC from the haematon fraction was low (around 5% of the whole TNC harvested), the GM-CFU population accounted for 24 ± 8% of the total GM-CFU collected from healthy donors, 21 ± 13% in breast cancer, 33 ± 19% in Hodgkin's disease, 21 ± 18% in non-Hodgkin's lymphoma and 13 ± 13% in AML patients ( Table 1) .
The haematon fraction contained significantly fewer progenitor cells than the filtered buffy coat in each patient group, but, individuals differed widely. The haematon fraction of healthy donors (n = 8), patients with breast cancer (n = 10; P Ͼ 0.05) and patients with Hodgkin's disease (n = 4; P Ͼ 0.05) provided the most TNC, HPP-CFC and GM-CFU progenitor cells. More variable numbers of cells were recovered from patients with non-Hodgkin's lymphoma (n = 7; P Ͼ 0.05) but significantly fewer cells were obtained from AML patients (n = 6; TNC: P = 0.05; HPP-CFC: P Ͻ 0.01; GM-CFU: P Ͻ 0.05; Table 1 ). In 12 of 35 cases (34%) the haematon fraction contained more than 30% of the total GM-CFU, and in two cases (5.7%) there were more progenitor cells in the haematon fraction than in the buffy coat pool.
The variable GM-CFU values for the patients were not due to the total BM volume (usually 1.4-1.6 l), or to the TNC mass harvested. However, there was a significant correlation with the clinical status when all patients were analysed together: the GM-CFU recovery in the haematon fraction was 19.8 ± 11% in patients at CR1, 31 ± 15 % at CR2 (P Ͼ 0.05) and 4.7 ± 3% at PR (P Ͻ 0.01).
The haematon fractions in allo-HSCT donors had fewer blood lymphocytes (CD4: 2.8 ± 1.2%, CD8: 4.4 ± 3.1% and CD20: 4.8 ± 2.5%) than the buffy coat (CD4: 20.1 ± 8%, P Ͻ 0.01; CD8: 11.5 ± 4%, P Ͻ 0.05 and CD20: 12.2 ± 3.5%, P Ͻ 0.01, n = 6).
Frequency of haemopoietic progenitor cells in the buffy coat and haematon fractions
Analysis of enzymatically dissociated BM fractions showed that colony-forming progenitor cells were more frequent in the haematon fraction than in the buffy coat-derived MNC fraction. There were 113 ± 55 cluster-forming and 87 ± 44 colony-forming GM-CFU, and 7.9 ± 5 HPP-CFC in 10 5 buffy coat-derived MNC (n = 23). The cluster-forming GM-CFU were enriched 1.54 ± 0.6-fold in the haematon fraction and the colony-forming GM-CFU by 2.3 ± 0.7-fold (n = 23; P Ͻ 0.05); the HPP-CFC was enriched 2.8 ± 1.1-fold (n = 21; P Ͻ 0.05).
The buffy coat and haematon fractions were also tested in miniaturized LTC for their capacity to initiate long-term haematopoiesis in the presence of an irradiated stromal feeder layer. LDA showed that the frequency of day 35 LTC-IC/CAFC was 1/5800 in the haematon/MNC and 1/21300 in the buffy coat/MNC fraction in human cell cultures (n = 7; 3.5 ± 0.8-fold enrichment; P Ͻ 0.01) (Figure 2) .
Purification of CD34 + cells from haematons and expansion in stroma-free suspension culture
The CD34
+ cells accounted for 3.4 ± 1.4% of cells in the haematons and 1.4 ± 1.2% in the buffy coat fraction (n = 10; P Ͻ 0.05). CD34 + cells were purified from 10 8 enzymatically dissociated cells by MACS: the total cell recovery was 5.2 ± 3.1 (1.6-8.9) × 10 6 (n = 5), and immunofluorescence analysis showed that CD34 + cells accounted for 50.4 ± 19.5% (25-78) of the positively sorted fraction. The recovery of GM-CFU in the CD34 + cell fractions was 128% (34-256) of the starting material, indicating that the CD34 − cells contained some colony inhibitory factors. The CD34 + fraction was 27-fold (5-64) enriched in HPP-CFC and 17-fold (5-54) enriched in GM-CFU progenitor cells over the starting population. 10 3 purified CD34 + cells from the buffy coat and haematon fractions were studied in semisolid colony assays. There was 48 ± 7 GM-CFU and 3 ± 1.5 HPP-CFU in the buffy coat and 53 ± 5 GM-CFU and 3.5 ± 1 HPP-CFU in the haematon cultures (n = 2; P Ͼ 0.05).
The expansion potential of 10 5 purified CD34 + cells was determined by serial measurements of the output of TNC, GM-CFU and HPP-CFC populations in stroma-free suspension culture. TNC expansion was 400 to 6000-fold on day 21 (acrophase), GM-CFU expansion was 300 to 3500-fold on day 17, and HPP-CFC expansion was 10 to 80-fold on days 10-12 in culture (n = 6; Figure 3 ).
Cell production ability in LTC of buffy coat and haematon
Aliquots (5 × 10 5 ) of washed cells from the buffy coat and haematon fractions were seeded in 2 ml LTC medium in 24-well tissue culture dishes. Phase contrast microscopy showed that, while initially there were fewer primary F-CFU in the buffy coat cultures, both cell fractions developed a stationary semi-confluent layer after 8-10 days in culture. Cell viability studies using Annexin-V-PI double labelling showed that Annexin-V only cells accounted for less than 2%, and double labelled apoptotic bodies, mainly derived from late erythroid cells accounted for 5-15% during the first week in culture. There was no statistically significant difference between the two culture systems.
The TNC, GM-CFU and HPP-CFC populations in the non-adherent and adherent cell compartments were monitored. The TNC and GM-CFU populations in the nonadherent fraction declined, while those in the adherent layer of the buffy coat cultures gradually expanded ( Figure 4a) ; those in both compartments expanded in the human haematon cultures (Figure 4b ). There was a 25-fold excess of GM-CFU on day 14 (acrophase) and a three-fold excess after 28 days in haematon LTCs over the buffy coat cultures.
Evidence for high numbers of stromal cell-associated progenitor cells in the haematon
The relative richness of the haematon in progenitor cells cannot totally explain the much greater cell amplification obtained in LTCs. We therefore investigated the possibility that the greater amplification in haematon LTCs was due to the presence of more stromal cell-associated haemopoietic progenitor cells.
The association of HPP-CFC and GM-CFU with stromal cells was studied in cultures of human haematon and buffy coat. Quiescent stromal cell progenitors associated with haemopoietic CFUs were quantitated by setting up standard methylcellulose cultures and isolating individual HPP-CFU and pooled GM-CFU colonies 28 days later; these were plated in liquid cultures. Buffy coat-derived HPP-CFCs (n = 75) and GM-CFUs did not include stromal cell progenitors, unlike haematon-derived colonies, where 39 of the 107 HPP-CFC (36%) generated monofocal F-CFU in secondary LTC (Table 2 ).
Discussion
This study shows that large numbers of stromal cells and associated haemopoietic progenitor cells can be recovered from the filters that are used to remove marrow particles immediately after large-scale BM harvesting. The filterretained material is composed of preformed cell aggregates, haematons, which have been identified in human, monkey and mouse BM. 13, 14, 40 The definition and characterisation of the haematon is important for both theoretical and methodological reasons.
First, our data support the notion that the mammalian BM is not a homogenous mixture of interacting cell types, but it is composed of two main compartments that can be separated physically, an abundant buffy coat suspension and a cohort of native cell aggregates, the haematons. The well-defined association of cells in intact BM was described earlier based on in situ ultrastructural observations, 46 indirect functional assays of fractionated BM 13, 40, 47 and cell marker analysis. 48 The absolute dependence of HSCs on stromal cells for long-term expansion and development was confirmed in LTBM mass culture [35] [36] [37] and in miniaturized LTC systems. 38, 39, [43] [44] [45] [46] [47] [48] [49] These studies established that the physiological functions of HSCs are maintained by specialized stromal cell 'niches', although the location and number of these rare, critical cell associations in vivo remain to be defined. The results presented here extend previous work and show that large numbers of stromal cell-associated haemopoietic progenitor cells, including putative HSCs, can be recovered from the filter-retained human or rapidly sedimenting mouse haematon fractions. 50 The haematon encloses erythroblastic islands and granulocytic CAs, and in mouse it is enriched three-fold in CFU-S d12 and cells with marrow repopulating ability (MRA), 40 indicating that the haematon units include HSCs which are critical for long-term BM regeneration. The present limiting dilution analysis shows that there are 3.5 times more LTC-IC/CAFC(w5) in the haematons (1/5800) than in the buffy coats (1/21 300) of human isolates. These values are within the ranges reported by others for normal BM. The frequency of LTC-IC/CAFC(w5) was about 1/13 000 in human unfractionated MNC 44, 45 and 1/30 000 in unseparated mouse BM. 43, 49 In fractionated mouse BM the frequency of CAFC was The MNC and the haematon fractions were dissociated in collagenase/dispase. 10 5 cells were cultured in methylcellulose/agar medium with IL-1␤, IL-3, GM-CSF, G-CSF and M-CSF. The GM-CFU were counted at day 14, and the HPP-CFU at day 28. The presence of F-CFU in HPP or in GM-CFUs was determined in secondary LTC. The HPP-CFUs were picked up individually, while the GMCFUs were pooled, dissociated and cultured in 2 ml liquid medium containing 5 mg bFGF and HGFs. The stromal F-CFU were identifed at 2 weeks in culture.
1/11 500 in the aggregate fraction, and four-fold lower (1/48 000) in the deaggregated marrow suspension.
The reproductive capacity of separated buffy coat and haematon fractions was assessed with LTBMCs that imitate many functions of the marrow microenvironment. Both haematon and buffy coat rapidly developed a confluent stromal layer, but the haematon generated more GM-CFU and HPP-CFC than did the buffy coat on days 14 and 28 of LTC. The murine LTBMC provides a tool with which to study the relationship of myelopoiesis to B lymphocytopoiesis at the level of primitive HSCs. 49, 51 A recent study showed that murine haematon LTCs generated 10 times more B lymphocytes than did the buffy coat cultures 3 weeks after conversion of myelopoiesis to B lymphopoiesis. 50 Funk et al 47 detected no significant difference in early, colony-forming B lymphocytes among the aggregate and suspension BM fractions immediately after isolation. Because committed B cell progenitors rapidly die in myeloid LTC conditions these results indicate that the haematon contains more stromal cell-associated myelolymphopoietic HSCs than does the buffy coat fraction. We have also shown that in the mouse femur almost all the native stromal cell-associated CAFC were in the haematon fraction. 50 The core structure in the haematon may be a primordial niche in the BM because it can generate haemopoietic progenitor cells autonomously in LTC in the absence of irradiated feeder cells and any 'community effect' from neighbouring cells.
The preferential location of haemopoietic niches, the greater frequency of LTC-IC/CAFC and common myelo-lymphopoietic HSCs, and the higher percentage of myeloid cells rather than late erythroid cells 13, 40 in the haematon fraction all contribute to and explain the greater cell production in haematon LTCs than in buffy coat LTCs. Stromal cell progenitors may form stable association with HPP-CFC in human haematons, which can be isolated and expanded in secondary LTC. These results support the notion that stromal cells in the haematon provide specific territories for regulatory factors that control the expansion and differentiation of normal myelo-lymphopoietic HSCs. Thus the haematon model provides a tool for in situ analysis of the molecular mechanisms that regulate activation, self-renewal and differentiation commitment of native, stromal cell-associated HSCs.
A finding of practical importance is that the filterretained haematon fraction is a good source for experimental and preclinical studies of stromal cells and potentially transplantable HSCs and CD34 + cells. Several methods have been developed recently to obtain adequate numbers of normal HSCs, which are suitable for definitive, long-term marrow repopulation following transplantation, to improve their purity [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] and to standardize the in vitro assay systems that accurately detect these critical cells. 39, 40, [42] [43] [44] [45] High-dose chemotherapy with autologous PB-HSC and/or BM-HSC support has become the most effective and widely used treatment for solid tumours, Hodgkin's disease and intermediate-and high-grade nonHodgkin's lymphoma. The use of mobilised PB-HSC, with or without growth factor stimulation, has considerably simplified the routine technique and improved the efficacy of auto-HSCT. Experiments with PB-HSCT have shown that all the important precursor cells required for long-term engraftment are present in mobilized PB, not needing other cellular elements from the BM. But recent studies indicate that the proliferative potential of LTC-ICs collected from PB during mobilization for PB-HSCT is significantly lower than that of LTC-ICs from normal donor blood or bone marrow samples. 52 Other studies have shown that cytotoxic chemotherapy and irradiation adversely affect the yield of mobilized PB-HSCs. 3, 5 There is thus a need for new techniques that provide more transplantable HSCs and for optimized transplantation schedules.
We have shown that the total number of progenitor cells (5-40 × 10 6 CD34 + cells; 0.49-2.67 × 10 6 GM-CFU, 20-115 × 10 3 HPP-CFU) that can be recovered from the filters of allo-HSCT donors might be sufficient for a second transplantation in certain cases, as a successful HSCT requires at least 10 6 CD34 + cells 20 or 0.1-2 × 10 5 GM-CFU 2,53,54 per kg body weight. In 2/27 cases the haematon fraction contained more GM-CFU than the buffy coat, and in 8/27 cases it contained more than 30% of the total GM-CFU harvested. Cell recoveries from the different patient groups, except LAM, were not significantly different, however, significantly fewer progenitor cells were recovered from patients in PR than from patients in CR1/CR2. This study also shows that CD34 + cells isolated from the haematon fraction are enriched in HPP-CFC d28 that can be expanded with HGFs in stroma-free suspension culture. Ex vivo expanded HSCs may be an attractive source of cells to accelerate haematological recovery, to reduce graft size and to purge metastatic tumour cells. The range and rate of cell production in haematon-derived CD34 + cell cultures are comparable to published data for CD34 + cells purified from the umbilical cord blood, 26, 28 peripheral blood 23 or normal BM. 25, 28 The number of HPP-CFC increased 10-to 80-fold in stroma-free suspension culture, indicating that haematon-derived CD34 + cells include a more primitive cell population that significantly expands the HPP-CFC compartment within 10-12 days in culture.
We conclude that the haematon fraction contains large numbers of stromal cells and stromal cell-associated haemopoietic progenitor cells, and provides a safe, economical source of cells. The filter-retained haematon fraction could be dissociated and stored frozen for emergency use in auto-HSCT, or the CD34 + progenitors and stromal cells could be used in developmental protocols to obtain more transplantable HSCs, doing away with repeated BM harvesting. Further clinical investigations 55 are required to answer the important question of whether the filter-retained haematon fraction can be used to treat patients.
